You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEsmolol
Accession NumberDB00187  (APRD00954)
TypeSmall Molecule
GroupsApproved
DescriptionEsmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.
Structure
Thumb
Synonyms
(±)-esmolol
(±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester
Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate
methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BreviblocInjection10 mg/mLIntravenousBaxter Healthcare Corporation1986-12-31Not applicableUs
BreviblocInjection, solution10 mg/mLIntravenousGeneral Injectables & Vaccines2010-07-01Not applicableUs
BreviblocInjection20 mg/mLIntravenousBaxter Healthcare Corporation1986-12-31Not applicableUs
BreviblocInjection10 mg/mLIntravenousBaxter Healthcare Corporation1986-12-31Not applicableUs
Brevibloc Injection 10mg/mlSolution10 mgIntravenousBaxter Corporation1996-08-16Not applicableCanada
Brevibloc Injection 250mg/mlLiquid250 mgIntravenousBaxter Corporation1997-01-172007-06-27Canada
Brevibloc Liq IV 10mg/mlLiquid10 mgIntravenousOhmeda Pharmaceutical Products, Division Of Boc Canada Limited1994-12-311996-09-26Canada
Brevibloc Liq IV 250mg/mlLiquid250 mgIntravenousOhmeda Pharmaceutical Products, Division Of Boc Canada Limited1994-12-311997-08-25Canada
Brevibloc Premixed InjectionSolution10 mgIntravenousBaxter Corporation2008-09-12Not applicableCanada
EsmololInjection10 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-04-01Not applicableUs
Esmolol HydrochlorideInjection10 mg/mLIntravenousWest Ward Pharmaceutical Corporation1986-12-31Not applicableUs
Esmolol HydrochlorideInjection10 mg/mLIntravenousBaxter Healthcare Corporation1986-12-31Not applicableUs
Esmolol HydrochlorideInjection10 mg/mLIntravenousCardinal Health1986-12-31Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Esmolol HydrochlorideInjection, solution10 mg/mLIntravenousAmerican Regent, Inc.2016-01-01Not applicableUs
Esmolol HydrochlorideInjection, solution100 mg/10mLIntravenousAuro Medics Pharma Llc2015-07-23Not applicableUs
Esmolol HydrochlorideInjection10 mg/mLIntravenousGENERAL INJECTABLES AND VACCINES, INC.2015-09-10Not applicableUs
Esmolol HydrochlorideInjection, solution10 mg/mLIntravenousMylan Institutional LLC2013-02-21Not applicableUs
Esmolol HydrochlorideInjection10 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Esmolol HydrochlorideInjection, solution10 mg/mLIntravenousFresenius Kabi USA, LLC2004-11-30Not applicableUs
Esmolol HydrochlorideInjection10 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2012-06-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Esmolol hydrochloride
81161-17-3
Thumb
  • InChI Key: GEKNCWBANDDJJL-UHFFFAOYSA-N
  • Monoisotopic Mass: 331.155036032
  • Average Mass: 331.835
DBSALT000586
Categories
UNIIMDY902UXSR
CAS number81147-92-4
WeightAverage: 295.374
Monoisotopic: 295.178358293
Chemical FormulaC16H25NO4
InChI KeyAQNDDEOPVVGCPG-UHFFFAOYSA-N
InChI
InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3
IUPAC Name
methyl 3-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)propanoate
SMILES
COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1
Pharmacology
IndicationFor the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionSimilar to other beta-blockers, esmolol blocks the agonistic effect of the sympathetic neurotransmitters by competing for receptor binding sites. Because it predominantly blocks the beta-1 receptors in cardiac tissue, it is said to be cardioselective. In general, so-called cardioselective beta-blockers are relatively cardioselective; at lower doses they block beta-1 receptors only but begin to block beta-2 receptors as the dose increases. At therapeutic dosages, esmolol does not have intrinsic sympathomimetic activity (ISA) or membrane-stabilizing (quinidine-like) activity. Antiarrhythmic activity is due to blockade of adrenergic stimulation of cardiac pacemaker potentials. In the Vaughan Williams classification of antiarrhythmics, beta-blockers are considered to be class II agents.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Related Articles
AbsorptionRapidly absorbed, steady-state blood levels for dosages from 50-300 µg/kg/min (0.05-0.3 mg/kg/mm) are obtained within five minutes.
Volume of distributionNot Available
Protein binding55% bound to human plasma protein, while the acid metabolite is 10% bound.
Metabolism

Rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Mainly in red blood cells to a free acid metabolite (with 1/1500 the activity of esmolol) and methanol.

SubstrateEnzymesProduct
Esmolol
Not Available
MethanolDetails
Route of eliminationConsistent with the high rate of blood-based metabolism of esmolol hydrochloride, less than 2% of the drug is excreted unchanged in the urine. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate. Excretion of the acid metabolite is significantly decreased in patients with renal disease, with the elimination half-life increased to about ten-fold that of normals, and plasma levels considerably elevated.
Half lifeRapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. The acid metabolite has an elimination half-life of about 3.7 hours.
Clearance
  • 20 L/kg/hr [Men]
ToxicitySymptoms of overdose include cardiac arrest, bradycardia, hypotension, electromechanical dissociation and loss of consciousness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Esmolol Action PathwayDrug actionSMP00301
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Esmolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Esmolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Esmolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Esmolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Esmolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideEsmolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Esmolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Esmolol is combined with Acetylcholine.Approved
AcetyldigitoxinEsmolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Esmolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Esmolol.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Esmolol.Approved, Illicit
AlfuzosinEsmolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Esmolol is combined with Aliskiren.Approved, Investigational
AmbenoniumAmbenonium may increase the bradycardic activities of Esmolol.Approved
Ambroxol acefyllinateEsmolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineThe risk or severity of adverse effects can be increased when Esmolol is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Esmolol is combined with Amiloride.Approved
AminophyllineEsmolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Esmolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Esmolol.Approved, Illicit
AmodiaquineThe metabolism of Esmolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Esmolol is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Esmolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Esmolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Esmolol.Approved
AnvirzelEsmolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Esmolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Esmolol.Approved, Investigational
ArbutamineEsmolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Esmolol is combined with Arecoline.Experimental
ArformoterolEsmolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Esmolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Esmolol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Esmolol is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Esmolol is combined with Atenolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Esmolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Esmolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Esmolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Esmolol.Approved, Investigational
BambuterolEsmolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Esmolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Esmolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Esmolol is combined with Bendroflumethiazide.Approved
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Esmolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Illicit
BepridilThe risk or severity of adverse effects can be increased when Esmolol is combined with Bepridil.Approved, Withdrawn
BeractantEsmolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Esmolol is combined with Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Esmolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Esmolol.Investigational
BisoprololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Esmolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Esmolol is combined with Bortezomib.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Esmolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Esmolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Esmolol.Investigational
BucindololEsmolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Esmolol is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Esmolol.Approved, Investigational
CabergolineEsmolol may increase the vasoconstricting activities of Cabergoline.Approved
CalfactantEsmolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Esmolol is combined with Carbachol.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Esmolol is combined with Carbetocin.Approved
CarprofenCarprofen may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Esmolol is combined with Carteolol.Approved
CarvedilolEsmolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Esmolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Esmolol.Approved, Investigational
CeliprololEsmolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibEsmolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Esmolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Esmolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Esmolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
ChlorpropamideEsmolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Esmolol is combined with Chlorthalidone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Cilnidipine.Approved
ClenbuterolEsmolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Esmolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Esmolol is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Esmolol.Approved
ClozapineThe risk or severity of adverse effects can be increased when Esmolol is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Esmolol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Esmolol.Vet Approved
CrizotinibEsmolol may increase the bradycardic activities of Crizotinib.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Esmolol.Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Esmolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Esmolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Esmolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Esmolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Esmolol.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Esmolol is combined with Desflurane.Approved
DeslanosideEsmolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Esmolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Esmolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Esmolol is combined with Diclofenamide.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Esmolol.Approved
DigitoxinEsmolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinEsmolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Esmolol is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Esmolol is combined with Dinutuximab.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Esmolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Esmolol.Approved
DobutamineEsmolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Esmolol.Approved
DoxazosinEsmolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Esmolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Esmolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
DuloxetineEsmolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Esmolol.Investigational
DyphyllineEsmolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Esmolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Esmolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Esmolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Esmolol.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Esmolol is combined with Enalaprilat.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Esmolol is combined with EPIBATIDINE.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Esmolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Esmolol is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Esmolol is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Eprosartan.Approved
Ergoloid mesylateEsmolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineEsmolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Esmolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Esmolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Esmolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Esmolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EtoperidoneThe serum concentration of Esmolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Esmolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Esmolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Esmolol.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Esmolol.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Esmolol is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Esmolol.Approved
FenoterolEsmolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Esmolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Esmolol.Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Fimasartan.Approved
FingolimodEsmolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Esmolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Esmolol.Vet Approved
FluoxetineThe serum concentration of Esmolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Esmolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Esmolol.Approved, Investigational
FormoterolEsmolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Esmolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Esmolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Esmolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Esmolol.Approved, Nutraceutical
GlibornurideEsmolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideEsmolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideEsmolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideEsmolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneEsmolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideEsmolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideEsmolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Esmolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Esmolol is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Esmolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Esmolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Esmolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Esmolol.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Esmolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Esmolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Esmolol is combined with Hydroflumethiazide.Approved
HydroxychloroquineThe metabolism of Esmolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Esmolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Esmolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Esmolol.Approved
IloprostThe risk or severity of adverse effects can be increased when Esmolol is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Esmolol is combined with Imipramine.Approved
IndacaterolEsmolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Esmolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Esmolol is combined with Indapamide.Approved
IndomethacinIndomethacin may decrease the antihypertensive activities of Esmolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Esmolol.Withdrawn
IndoraminEsmolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkEsmolol may increase the hypoglycemic activities of Insulin Pork.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Esmolol is combined with Isocarboxazid.Approved
IsoetarineEsmolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Esmolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Esmolol.Approved, Withdrawn
IsoprenalineEsmolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Esmolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Esmolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Esmolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Esmolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Isradipine.Approved
IvabradineEsmolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Esmolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Esmolol.Approved
LabetalolEsmolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Lacidipine.Approved
LacosamideEsmolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideEsmolol may increase the bradycardic activities of Lanreotide.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Esmolol.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Esmolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Esmolol is combined with Levobupivacaine.Approved
LevodopaEsmolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Esmolol can be increased when it is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Esmolol is combined with Levosimendan.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Esmolol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Esmolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Esmolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Esmolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Esmolol.Approved
LucinactantEsmolol may increase the bradycardic activities of Lucinactant.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Esmolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Esmolol.Approved
MalathionMalathion may increase the bradycardic activities of Esmolol.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Esmolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Esmolol.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Esmolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Esmolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Esmolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Esmolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Esmolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Esmolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Esmolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Esmolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Esmolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Esmolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Esmolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Esmolol.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Esmolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Esmolol is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Esmolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Esmolol.Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Esmolol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Esmolol is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metoprolol.Approved, Investigational
MidodrineEsmolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Esmolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Esmolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Esmolol is combined with Minoxidil.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Esmolol.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Moexipril.Approved
MoricizineMoricizine may increase the hypotensive activities of Esmolol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Esmolol is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Esmolol is combined with Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Esmolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Esmolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Esmolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Esmolol.Approved
NadololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Esmolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Esmolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Esmolol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Esmolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Esmolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Esmolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Esmolol is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Esmolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Esmolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Esmolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Esmolol.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Esmolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Esmolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitroprusside.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Esmolol is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the bradycardic activities of Esmolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Olmesartan.Approved, Investigational
OlodaterolEsmolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Esmolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Esmolol.Approved
OrciprenalineEsmolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Esmolol.Vet Approved
OuabainEsmolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Esmolol.Approved
OxprenololThe risk or severity of adverse effects can be increased when Esmolol is combined with Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Esmolol.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Esmolol is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
PapaverineThe risk or severity of adverse effects can be increased when Esmolol is combined with Papaverine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Esmolol.Approved
ParoxetineThe serum concentration of Esmolol can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideEsmolol may increase the bradycardic activities of Pasireotide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Esmolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Esmolol.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Esmolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Esmolol.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Esmolol is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Esmolol.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Esmolol is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Esmolol is combined with Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Esmolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Esmolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Esmolol.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Esmolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Esmolol is combined with Pipamperone.Approved
PirbuterolEsmolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Esmolol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Esmolol.Approved, Investigational
Poractant alfaEsmolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Esmolol is combined with Pramipexole.Approved, Investigational
PrazosinEsmolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Esmolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Esmolol.Approved, Vet Approved
ProcaterolEsmolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Esmolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Esmolol.Approved
PropafenoneThe serum concentration of Esmolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Esmolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Esmolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Esmolol is combined with Propranolol.Approved, Investigational
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Esmolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Esmolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Esmolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Esmolol.Approved
RasagilineThe risk or severity of adverse effects can be increased when Esmolol is combined with Rasagiline.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Esmolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Esmolol is combined with Remifentanil.Approved
ReserpineReserpine may increase the hypotensive activities of Esmolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Esmolol.Experimental, Investigational
RifampicinThe serum concentration of Esmolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Esmolol can be decreased when it is combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Esmolol is combined with Riociguat.Approved
RisperidoneEsmolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineEsmolol may decrease the bronchodilatory activities of Ritodrine.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Esmolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Esmolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Esmolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Esmolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Esmolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Esmolol is combined with Sacubitril.Approved
SalbutamolEsmolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Esmolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
SalmeterolEsmolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Esmolol.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Esmolol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Esmolol is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Esmolol.Approved, Investigational
SertralineThe serum concentration of Esmolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Esmolol is combined with Sevoflurane.Approved, Vet Approved
SilodosinEsmolol may increase the orthostatic hypotensive activities of Silodosin.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Esmolol is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Esmolol is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Esmolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Esmolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Esmolol is combined with Streptokinase.Approved
SufentanilEsmolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Esmolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Esmolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Esmolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Esmolol.Withdrawn
TamsulosinEsmolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Telmisartan.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Esmolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Esmolol.Vet Approved
TerazosinEsmolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineEsmolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Esmolol.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Esmolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineEsmolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Esmolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Esmolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Esmolol.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Esmolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Esmolol.Approved
TimololThe risk or severity of adverse effects can be increased when Esmolol is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Esmolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Esmolol.Approved, Investigational
TolazamideEsmolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Esmolol is combined with Tolazoline.Approved, Vet Approved
TolbutamideEsmolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Esmolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Esmolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Esmolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Esmolol is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Esmolol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Esmolol is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Esmolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Esmolol is combined with Triamterene.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Esmolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Esmolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
TrimazosinEsmolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Esmolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Esmolol.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Esmolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Esmolol.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when Esmolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Esmolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Esmolol is combined with Verapamil.Approved
VilanterolEsmolol may decrease the bronchodilatory activities of Vilanterol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Esmolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Esmolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Esmolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Esmolol.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US4593119
General ReferencesNot Available
External Links
ATC CodesC07AB09
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (56.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7023
Blood Brain Barrier-0.9645
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.6511
P-glycoprotein inhibitor INon-inhibitor0.8625
P-glycoprotein inhibitor IINon-inhibitor0.7171
Renal organic cation transporterNon-inhibitor0.8605
CYP450 2C9 substrateNon-substrate0.8124
CYP450 2D6 substrateSubstrate0.663
CYP450 3A4 substrateNon-substrate0.5869
CYP450 1A2 substrateNon-inhibitor0.864
CYP450 2C9 inhibitorNon-inhibitor0.8789
CYP450 2D6 inhibitorNon-inhibitor0.8806
CYP450 2C19 inhibitorNon-inhibitor0.9585
CYP450 3A4 inhibitorNon-inhibitor0.8495
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9761
Ames testNon AMES toxic0.9066
CarcinogenicityNon-carcinogens0.9519
BiodegradationNot ready biodegradable0.6493
Rat acute toxicity1.9194 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9556
hERG inhibition (predictor II)Non-inhibitor0.774
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Baxter healthcare corp anesthesia critical care
  • App pharmaceuticals llc
  • Bedford laboratories
  • Bioniche pharma usa llc
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous20 mg/mL
SolutionIntravenous10 mg
LiquidIntravenous10 mg
LiquidIntravenous250 mg
InjectionIntravenous10 mg/mL
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous100 mg/10mL
Prices
Unit descriptionCostUnit
Brevibloc 250 mg/ml ampul13.21USD ml
Brevibloc 10 mg/ml vial2.21USD ml
Brevibloc 20 mg/ml iv bag1.54USD ml
Esmolol hcl 10 mg/ml vial1.26USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2410446 No2008-08-262022-01-02Canada
US6310094 Yes2001-07-122021-07-12Us
US6528540 Yes2001-07-122021-07-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery soluble as hydrochloride saltNot Available
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.144 mg/mLALOGPS
logP2.02ALOGPS
logP1.82ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.79 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity81.05 m3·mol-1ChemAxon
Polarizability33.68 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenol ether
  • Fatty acid ester
  • Alkyl aryl ether
  • Fatty acyl
  • Methyl ester
  • Secondary alcohol
  • Carboxylic acid ester
  • 1,2-aminoalcohol
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Jahn P, Eckrich B, Schneidrowski B, Volz-Zang C, Schulte B, Mutschler E, Palm D: Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor. Arzneimittelforschung. 1995 May;45(5):536-41. [PubMed:7612051 ]
  3. Volz-Zang C, Eckrich B, Jahn P, Schneidrowski B, Schulte B, Palm D: Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties. Eur J Clin Pharmacol. 1994;46(5):399-404. [PubMed:7957532 ]
  4. Kirshenbaum JM: Nonthrombolytic intervention in acute myocardial infarction. Am J Cardiol. 1989 Jul 18;64(4):25B-28B. [PubMed:2568748 ]
  5. Jacobs JR, Maier GW, Rankin JS, Reves JG: Esmolol and left ventricular function in the awake dog. Anesthesiology. 1988 Mar;68(3):373-8. [PubMed:2894187 ]
  6. Howie MB, Black HA, Zvara D, McSweeney TD, Martin DJ, Coffman JA: Esmolol reduces autonomic hypersensitivity and length of seizures induced by electroconvulsive therapy. Anesth Analg. 1990 Oct;71(4):384-8. [PubMed:1975995 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 03:55